Annual CFF
-$59.95 M
+$216.04 M+78.28%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual cash flow from financing activities is currently -$59.95 million, with the most recent change of +$216.04 million (+78.28%) on 31 December 2023. During the last 3 years, it has risen by +$250.60 million (+80.70%). LGND annual CFF is now -118.24% below its all-time high of $328.58 million, reached on 31 December 2018.LGND Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$55.08 M
+$45.59 M+480.34%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly cash flow from financing activities is currently $55.08 million, with the most recent change of +$45.59 million (+480.34%) on 30 September 2024. Over the past year, it has increased by +$51.81 million (+1584.40%). LGND quarterly CFF is now -91.02% below its all-time high of $613.53 million, reached on 30 June 2018.LGND Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$82.07 M
+$51.81 M+171.23%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM cash flow from financing activities is currently $82.07 million, with the most recent change of +$51.81 million (+171.23%) on 30 September 2024. Over the past year, it has increased by +$152.63 million (+216.31%). LGND TTM CFF is now -87.72% below its all-time high of $668.41 million, reached on 30 September 2018.LGND TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +78.3% | +1584.4% | +216.3% |
| 3 y3 years | +80.7% | +10000.0% | +148.4% |
| 5 y5 years | -118.2% | +126.1% | +111.0% |
LGND Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +80.7% | at high | +132.3% | at high | +129.7% |
| 5 y | 5 years | -118.2% | +87.6% | at high | +119.7% | at high | +111.0% |
| alltime | all time | -118.2% | +87.6% | -91.0% | +115.9% | -87.7% | +111.0% |
Ligand Pharmaceuticals Incorporated Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $55.08 M(+480.3%) | $82.07 M(+171.2%) |
| June 2024 | - | $9.49 M(-22.1%) | $30.26 M(-164.4%) |
| Mar 2024 | - | $12.18 M(+129.2%) | -$46.99 M(-21.6%) |
| Dec 2023 | -$59.95 M(-78.3%) | $5.32 M(+62.5%) | -$59.95 M(-15.0%) |
| Sept 2023 | - | $3.27 M(-104.8%) | -$70.56 M(-38.5%) |
| June 2023 | - | -$67.76 M(+8642.8%) | -$114.66 M(+7.8%) |
| Mar 2023 | - | -$775.00 K(-85.4%) | -$106.34 M(-61.5%) |
| Dec 2022 | -$275.99 M(+100.3%) | -$5.30 M(-87.0%) | -$275.99 M(+3.6%) |
| Sept 2022 | - | -$40.83 M(-31.3%) | -$266.53 M(+17.9%) |
| June 2022 | - | -$59.44 M(-65.1%) | -$226.08 M(+4.4%) |
| Mar 2022 | - | -$170.42 M(-4192.7%) | -$216.55 M(+57.2%) |
| Dec 2021 | -$137.76 M(-55.6%) | $4.16 M(-1181.6%) | -$137.76 M(-18.7%) |
| Sept 2021 | - | -$385.00 K(-99.2%) | -$169.45 M(-1.9%) |
| June 2021 | - | -$49.91 M(-45.5%) | -$172.78 M(+40.6%) |
| Mar 2021 | - | -$91.64 M(+232.9%) | -$122.88 M(-60.4%) |
| Dec 2020 | -$310.55 M(-36.0%) | -$27.53 M(+642.8%) | -$310.55 M(-15.3%) |
| Sept 2020 | - | -$3.71 M(>+9900.0%) | -$366.71 M(-36.1%) |
| June 2020 | - | -$5000.00(-100.0%) | -$574.32 M(-6.1%) |
| Mar 2020 | - | -$279.31 M(+233.7%) | -$611.90 M(+26.1%) |
| Dec 2019 | -$485.17 M(-247.7%) | -$83.69 M(-60.4%) | -$485.17 M(-35.2%) |
| Sept 2019 | - | -$211.31 M(+462.1%) | -$748.56 M(+56.5%) |
| June 2019 | - | -$37.59 M(-75.4%) | -$478.33 M(-376.8%) |
| Mar 2019 | - | -$152.58 M(-56.0%) | $172.78 M(-47.4%) |
| Dec 2018 | $328.58 M(-4467.7%) | -$347.08 M(-689.1%) | $328.58 M(-50.8%) |
| Sept 2018 | - | $58.92 M(-90.4%) | $668.41 M(+9.4%) |
| June 2018 | - | $613.53 M(>+9900.0%) | $610.90 M(<-9900.0%) |
| Mar 2018 | - | $3.22 M(-144.4%) | -$2.63 M(-65.0%) |
| Dec 2017 | -$7.52 M(+50.6%) | -$7.25 M(-616.7%) | -$7.52 M(-15.2%) |
| Sept 2017 | - | $1.40 M(<-9900.0%) | -$8.87 M(+2.6%) |
| June 2017 | - | -$5000.00(-99.7%) | -$8.65 M(+20.6%) |
| Mar 2017 | - | -$1.67 M(-80.6%) | -$7.17 M(+43.6%) |
| Dec 2016 | -$4.99 M(-159.7%) | -$8.60 M(-628.1%) | -$4.99 M(-198.3%) |
| Sept 2016 | - | $1.63 M(+10.9%) | $5.08 M(+3.4%) |
| June 2016 | - | $1.47 M(+187.5%) | $4.91 M(-39.3%) |
| Mar 2016 | - | $511.00 K(-65.2%) | $8.09 M(-3.2%) |
| Dec 2015 | $8.36 M(-93.6%) | $1.47 M(+0.7%) | $8.36 M(-137.8%) |
| Sept 2015 | - | $1.46 M(-68.6%) | -$22.11 M(-115.9%) |
| June 2015 | - | $4.65 M(+495.3%) | $138.75 M(+5.9%) |
| Mar 2015 | - | $781.00 K(-102.7%) | $131.05 M(+0.8%) |
| Dec 2014 | $130.03 M(-890.0%) | -$29.00 M(-117.9%) | $130.03 M(-16.8%) |
| Sept 2014 | - | $162.32 M(-5408.0%) | $156.36 M(-2052.0%) |
| June 2014 | - | -$3.06 M(+1168.9%) | -$8.01 M(+9.6%) |
| Mar 2014 | - | -$241.00 K(-91.0%) | -$7.31 M(-55.6%) |
| Dec 2013 | -$16.46 M(-520.3%) | -$2.66 M(+30.0%) | -$16.46 M(+55.9%) |
| Sept 2013 | - | -$2.05 M(-13.2%) | -$10.56 M(+49.3%) |
| June 2013 | - | -$2.36 M(-74.9%) | -$7.07 M(+52.7%) |
| Mar 2013 | - | -$9.39 M(-390.2%) | -$4.63 M(-218.3%) |
| Dec 2012 | $3.92 M(-86.9%) | $3.23 M(+124.8%) | $3.92 M(+434.2%) |
| Sept 2012 | - | $1.44 M(+1654.9%) | $733.00 K(-204.1%) |
| June 2012 | - | $82.00 K(-109.8%) | -$704.00 K(-116.7%) |
| Mar 2012 | - | -$840.00 K(-1715.4%) | $4.21 M(-86.0%) |
| Dec 2011 | $30.00 M(<-9900.0%) | $52.00 K(+2500.0%) | $30.00 M(+0.8%) |
| Sept 2011 | - | $2000.00(-100.0%) | $29.77 M(+0.1%) |
| June 2011 | - | $5.00 M(-80.0%) | $29.73 M(+20.0%) |
| Mar 2011 | - | $24.95 M(<-9900.0%) | $24.78 M(<-9900.0%) |
| Dec 2010 | -$159.00 K(-95.7%) | -$178.00 K(+334.1%) | -$159.00 K(-250.0%) |
| Sept 2010 | - | -$41.00 K(-178.8%) | $106.00 K(+125.5%) |
| June 2010 | - | $52.00 K(+550.0%) | $47.00 K(-149.5%) |
| Mar 2010 | - | $8000.00(-90.8%) | -$95.00 K(-97.4%) |
| Dec 2009 | -$3.69 M | $87.00 K(-187.0%) | -$3.69 M(-7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2009 | - | -$100.00 K(+11.1%) | -$3.98 M(-5.5%) |
| June 2009 | - | -$90.00 K(-97.5%) | -$4.21 M(-6.6%) |
| Mar 2009 | - | -$3.58 M(+1683.6%) | -$4.50 M(+49.6%) |
| Dec 2008 | -$3.01 M(-99.1%) | -$201.00 K(-39.3%) | -$3.01 M(-59.3%) |
| Sept 2008 | - | -$331.00 K(-14.0%) | -$7.39 M(-57.7%) |
| June 2008 | - | -$385.00 K(-81.6%) | -$17.49 M(-94.1%) |
| Mar 2008 | - | -$2.09 M(-54.3%) | -$294.37 M(-10.2%) |
| Dec 2007 | -$327.70 M(-1084.1%) | -$4.58 M(-56.1%) | -$327.70 M(+12.8%) |
| Sept 2007 | - | -$10.43 M(-96.2%) | -$290.42 M(+3.8%) |
| June 2007 | - | -$277.26 M(+682.7%) | -$279.81 M(>+9900.0%) |
| Mar 2007 | - | -$35.42 M(-208.3%) | -$2.17 M(-106.5%) |
| Dec 2006 | $33.30 M(<-9900.0%) | $32.70 M(>+9900.0%) | $33.30 M(+5621.8%) |
| Sept 2006 | - | $179.00 K(-53.6%) | $582.00 K(-232.6%) |
| June 2006 | - | $386.00 K(+841.5%) | -$439.00 K(-55.1%) |
| Mar 2006 | - | $41.00 K(-270.8%) | -$978.00 K(+386.6%) |
| Dec 2005 | -$201.00 K(-102.5%) | -$24.00 K(-97.1%) | -$201.00 K(-8.6%) |
| Sept 2005 | - | -$842.00 K(+450.3%) | -$220.00 K(-107.3%) |
| June 2005 | - | -$153.00 K(-118.7%) | $3.00 M(-39.7%) |
| Mar 2005 | - | $818.00 K(-2002.3%) | $4.98 M(-37.1%) |
| Dec 2004 | $7.92 M(-75.4%) | -$43.00 K(-101.8%) | $7.92 M(+110.8%) |
| Sept 2004 | - | $2.38 M(+30.6%) | $3.75 M(-92.4%) |
| June 2004 | - | $1.82 M(-51.4%) | $49.67 M(-4.8%) |
| Mar 2004 | - | $3.75 M(-189.2%) | $52.18 M(+62.4%) |
| Dec 2003 | $32.13 M(-81.2%) | -$4.20 M(-108.7%) | $32.13 M(-82.8%) |
| Sept 2003 | - | $48.29 M(+1012.3%) | $186.47 M(+33.1%) |
| June 2003 | - | $4.34 M(-126.6%) | $140.13 M(-8.6%) |
| Mar 2003 | - | -$16.30 M(-110.9%) | $153.27 M(-10.4%) |
| Dec 2002 | $171.09 M(+380.7%) | $150.14 M(+7567.9%) | $171.09 M(+639.7%) |
| Sept 2002 | - | $1.96 M(-88.8%) | $23.13 M(+4.8%) |
| June 2002 | - | $17.48 M(+1050.6%) | $22.08 M(+234.7%) |
| Mar 2002 | - | $1.52 M(-30.2%) | $6.59 M(-81.5%) |
| Dec 2001 | $35.59 M(+196.0%) | $2.18 M(+141.1%) | $35.59 M(+4.4%) |
| Sept 2001 | - | $903.00 K(-54.8%) | $34.09 M(+2.2%) |
| June 2001 | - | $2.00 M(-93.5%) | $33.34 M(-14.3%) |
| Mar 2001 | - | $30.52 M(+4455.1%) | $38.91 M(+223.6%) |
| Dec 2000 | $12.03 M(-85.4%) | $670.00 K(+335.1%) | $12.03 M(-53.1%) |
| Sept 2000 | - | $154.00 K(-98.0%) | $25.66 M(-71.2%) |
| June 2000 | - | $7.57 M(+108.2%) | $89.00 M(+3.0%) |
| Mar 2000 | - | $3.63 M(-74.6%) | $86.43 M(+4.8%) |
| Dec 1999 | $82.50 M(+25.4%) | $14.30 M(-77.5%) | $82.50 M(-28.4%) |
| Sept 1999 | - | $63.50 M(+1170.0%) | $115.30 M(+77.1%) |
| June 1999 | - | $5.00 M(-1766.7%) | $65.10 M(-0.3%) |
| Mar 1999 | - | -$300.00 K(-100.6%) | $65.30 M(-0.8%) |
| Dec 1998 | $65.80 M(+80.3%) | $47.10 M(+254.1%) | $65.80 M(+27.8%) |
| Sept 1998 | - | $13.30 M(+155.8%) | $51.50 M(+32.7%) |
| June 1998 | - | $5.20 M(+2500.0%) | $38.80 M(+15.5%) |
| Mar 1998 | - | $200.00 K(-99.4%) | $33.60 M(-7.9%) |
| Dec 1997 | $36.50 M(-18.3%) | $32.80 M(+5366.7%) | $36.50 M(-18.5%) |
| Sept 1997 | - | $600.00 K(>+9900.0%) | $44.80 M(+3.2%) |
| June 1997 | - | $0.00(-100.0%) | $43.40 M(-0.7%) |
| Mar 1997 | - | $3.10 M(-92.5%) | $43.70 M(-2.2%) |
| Dec 1996 | $44.70 M(+154.0%) | $41.10 M(-5237.5%) | $44.70 M(+1141.7%) |
| Sept 1996 | - | -$800.00 K(-366.7%) | $3.60 M(-18.2%) |
| June 1996 | - | $300.00 K(-92.7%) | $4.40 M(+7.3%) |
| Mar 1996 | - | $4.10 M(-10.9%) | $4.10 M(-82.9%) |
| Dec 1995 | $17.60 M(-8.3%) | - | - |
| Mar 1995 | - | $4.60 M(-1633.3%) | $24.00 M(+25.0%) |
| Dec 1994 | $19.20 M | -$300.00 K(-101.5%) | $19.20 M(-1.5%) |
| Sept 1994 | - | $19.90 M(<-9900.0%) | $19.50 M(-4975.0%) |
| June 1994 | - | -$200.00 K(0.0%) | -$400.00 K(+100.0%) |
| Mar 1994 | - | -$200.00 K | -$200.00 K |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual cash flow from financing activities?
- What is the all time high annual CFF for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual CFF year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly CFF year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM cash flow from financing activities?
- What is the all time high TTM CFF for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM CFF year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual cash flow from financing activities?
The current annual CFF of LGND is -$59.95 M
What is the all time high annual CFF for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual cash flow from financing activities is $328.58 M
What is Ligand Pharmaceuticals Incorporated annual CFF year-on-year change?
Over the past year, LGND annual cash flow from financing activities has changed by +$216.04 M (+78.28%)
What is Ligand Pharmaceuticals Incorporated quarterly cash flow from financing activities?
The current quarterly CFF of LGND is $55.08 M
What is the all time high quarterly CFF for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly cash flow from financing activities is $613.53 M
What is Ligand Pharmaceuticals Incorporated quarterly CFF year-on-year change?
Over the past year, LGND quarterly cash flow from financing activities has changed by +$51.81 M (+1584.40%)
What is Ligand Pharmaceuticals Incorporated TTM cash flow from financing activities?
The current TTM CFF of LGND is $82.07 M
What is the all time high TTM CFF for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM cash flow from financing activities is $668.41 M
What is Ligand Pharmaceuticals Incorporated TTM CFF year-on-year change?
Over the past year, LGND TTM cash flow from financing activities has changed by +$152.63 M (+216.31%)